Skip to main content

Table 1 Demographic characteristics of 4446 patients with limited-disease small-cell lung cancer who received definite concurrent chemoradiotherapy

From: Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study

Variables LD stage (n = 4446)
Age, years 64 ± 8.28
 < 65 2187 (49.2)
 ≥65 2259 (50.8)
Sex (male/female) 3797 (85.4)/649 (14.6)
Comorbidities
 HBP 2361 (39.3)
 DM 1334 (22.2)
 Hypercholesterolemia 2314 (38.5)
First-line therapy
 Combination CRT
  Etoposide/platinum 4187 (94.2)
  Irinotecan/platinum 259 (5.8)
Second-line therapy
 Combination therapy
  Etoposide/platinum 151 (8.7)
  Irinotecan/platinum 774 (44.5)
 Single-agent therapy
  Etoposide 1 (0.1)
  Irinotecan 232 (13.3)
  Belotecan 342 (19.6)
  Topotecan 240 (13.8)
  1. Values are presented as mean ± standard deviation or number (%)
  2. LD, limited disease; HBP, hypertension; DM, diabetes mellitus; CRT, chemoradiotherapy